iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of iRadimed stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $100.04, for a total transaction of $500,200.00. Following the sale, the chief executive officer owned 2,250,000 shares of the company’s stock, valued at $225,090,000. The trade was a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

iRadimed Stock Performance

iRadimed stock traded down $1.23 during trading hours on Tuesday, hitting $98.95. The company had a trading volume of 55,132 shares, compared to its average volume of 72,170. The firm has a market cap of $1.26 billion, a P/E ratio of 56.54 and a beta of 1.12. The company has a 50-day moving average price of $100.06 and a two-hundred day moving average price of $87.98. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $107.90.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. The business had revenue of $22.69 million for the quarter, compared to analyst estimates of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.85%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were given a dividend of $0.20 per share. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. iRadimed’s dividend payout ratio is presently 45.71%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC grew its stake in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP purchased a new position in shares of iRadimed in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC grew its position in shares of iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 397 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of iRadimed during the 3rd quarter worth approximately $47,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IRMD. Roth Mkm restated a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. Lake Street Capital reiterated a “buy” rating and set a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, iRadimed currently has a consensus rating of “Moderate Buy” and an average price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.